206 related articles for article (PubMed ID: 36575438)
1. SMYD3 associates with the NuRD (MTA1/2) complex to regulate transcription and promote proliferation and invasiveness in hepatocellular carcinoma cells.
Yang Y; Qiu R; Zhao S; Shen L; Tang B; Weng Q; Xu Z; Zheng L; Chen W; Shu G; Wang Y; Zhao Z; Chen M; Ji J
BMC Biol; 2022 Dec; 20(1):294. PubMed ID: 36575438
[TBL] [Abstract][Full Text] [Related]
2. Amplification of SMYD3 promotes tumorigenicity and intrahepatic metastasis of hepatocellular carcinoma via upregulation of CDK2 and MMP2.
Wang Y; Xie BH; Lin WH; Huang YH; Ni JY; Hu J; Cui W; Zhou J; Shen L; Xu LF; Lian F; Li HP
Oncogene; 2019 Jun; 38(25):4948-4961. PubMed ID: 30842588
[TBL] [Abstract][Full Text] [Related]
3. SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters.
Zhang H; Zheng Z; Zhang R; Yan Y; Peng Y; Ye H; Lin L; Xu J; Li W; Huang P
Cell Death Dis; 2021 Jul; 12(8):731. PubMed ID: 34301921
[TBL] [Abstract][Full Text] [Related]
4. ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma.
Zhou Z; Jiang H; Tu K; Yu W; Zhang J; Hu Z; Zhang H; Hao D; Huang P; Wang J; Wang A; Xiao Z; He C
J Exp Clin Cancer Res; 2019 Jan; 38(1):18. PubMed ID: 30646949
[TBL] [Abstract][Full Text] [Related]
5. The ubiquitin ligase TRIM25 inhibits hepatocellular carcinoma progression by targeting metastasis associated 1 protein.
Zang HL; Ren SN; Cao H; Tian XF
IUBMB Life; 2017 Oct; 69(10):795-801. PubMed ID: 28861931
[TBL] [Abstract][Full Text] [Related]
6. Pterostilbene inhibits MTA1/HDAC1 complex leading to PTEN acetylation in hepatocellular carcinoma.
Qian YY; Liu ZS; Yan HJ; Yuan YF; Levenson AS; Li K
Biomed Pharmacother; 2018 May; 101():852-859. PubMed ID: 29635894
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of MTA1 by ERα contributes to protection hepatocellular carcinoma from tumor proliferation and metastasis.
Deng L; Yang H; Tang J; Lin Z; Yin A; Gao Y; Wang X; Jiang R; Sun B
J Exp Clin Cancer Res; 2015 Oct; 34():128. PubMed ID: 26503703
[TBL] [Abstract][Full Text] [Related]
8. Potential Role of microRNA-183 as a Tumor Suppressor in Hepatocellular Carcinoma.
Bian W; Zhang H; Tang M; Zhang S; Wang L; Liu L; Wang W
Cell Physiol Biochem; 2018; 51(5):2065-2072. PubMed ID: 30522116
[TBL] [Abstract][Full Text] [Related]
9. [Inhibition of SMYD3 gene expression by RNA interference induces apoptosis in human hepatocellular carcinoma cell line HepG2].
Xu JY; Chen LB; Xu JY; Yang Z; Wei HY; Xu RH
Ai Zheng; 2006 May; 25(5):526-32. PubMed ID: 16687068
[TBL] [Abstract][Full Text] [Related]
10. [Induction of SMYD3 by hepatitis B virus X gene in HepG2 cells].
Yang L; Ren J; He J; Chen LB
Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):297-300. PubMed ID: 19403031
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of SMYD3 Is Predictive of Unfavorable Prognosis in Hepatocellular Carcinoma.
Fei X; Ma Y; Liu X; Meng Z
Tohoku J Exp Med; 2017 Nov; 243(3):219-226. PubMed ID: 29187705
[TBL] [Abstract][Full Text] [Related]
12. Interaction of the hepatitis B virus X protein with the lysine methyltransferase SET and MYND domain-containing 3 induces activator protein 1 activation.
Hayashi M; Deng L; Chen M; Gan X; Shinozaki K; Shoji I; Hotta H
Microbiol Immunol; 2016 Jan; 60(1):17-25. PubMed ID: 26616333
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells.
Yoo YG; Na TY; Seo HW; Seong JK; Park CK; Shin YK; Lee MO
Oncogene; 2008 May; 27(24):3405-13. PubMed ID: 18264140
[TBL] [Abstract][Full Text] [Related]
14. SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration, and invasion in esophageal squamous cell carcinoma.
Zhu Y; Zhu MX; Zhang XD; Xu XE; Wu ZY; Liao LD; Li LY; Xie YM; Wu JY; Zou HY; Xie JJ; Li EM; Xu LY
Hum Pathol; 2016 Jun; 52():153-63. PubMed ID: 26980013
[TBL] [Abstract][Full Text] [Related]
15. Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration.
Chen LB; Xu JY; Yang Z; Wang GB
World J Gastroenterol; 2007 Nov; 13(43):5718-24. PubMed ID: 17963297
[TBL] [Abstract][Full Text] [Related]
16. RUNX2 recruits the NuRD(MTA1)/CRL4B complex to promote breast cancer progression and bone metastasis.
Yin X; Teng X; Ma T; Yang T; Zhang J; Huo M; Liu W; Yang Y; Yuan B; Yu H; Huang W; Wang Y
Cell Death Differ; 2022 Nov; 29(11):2203-2217. PubMed ID: 35534547
[TBL] [Abstract][Full Text] [Related]
17. SMYD3 overexpression indicates poor prognosis and promotes cell proliferation, migration and invasion in non‑small cell lung cancer.
Li J; Zhao L; Pan Y; Ma X; Liu L; Wang W; You W
Int J Oncol; 2020 Sep; 57(3):756-766. PubMed ID: 32705243
[TBL] [Abstract][Full Text] [Related]
18. MTA1 modulated by miR-30e contributes to epithelial-to-mesenchymal transition in hepatocellular carcinoma through an ErbB2-dependent pathway.
Deng L; Tang J; Yang H; Cheng C; Lu S; Jiang R; Sun B
Oncogene; 2017 Jul; 36(28):3976-3985. PubMed ID: 28288133
[TBL] [Abstract][Full Text] [Related]
19. Loss of MTA2-mediated downregulation of PTK7 inhibits hepatocellular carcinoma metastasis progression by modulating the FAK-MMP7 axis.
Hu HM; Lee HL; Liu CJ; Hsieh YH; Chen YS; Hsueh KC
Environ Toxicol; 2024 Apr; 39(4):1897-1908. PubMed ID: 38050825
[TBL] [Abstract][Full Text] [Related]
20. The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity.
Yao YL; Yang WM
J Biol Chem; 2003 Oct; 278(43):42560-8. PubMed ID: 12920132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
